11.06.2012 - The Innovative Medicines Initiative (IMI) has announced details on seven projects funded with a total budget of €215m.
The projects funded within the next five years include two coordinated by GlaxoSmithKline plc: model-based preclinical development of anti-tuberculosis (TB) drug combinations (PreDiCT-TB), which aim to make tuberculosis treatments more patient-friendly; and development of tools to predict immune response to biopharmaceuticals (ABIRISK). Sanofi is coordinating the DIRECT project to research patient stratification for personalised Type II diabetes treatments. Novartis AG and The University of Surrey (UK) are working on a project to develop biomarkers to test the safety of vaccines (BIOVACSAFE). A project coordinated by AstraZeneca plc is to develop tests for drug-induced liver injury (MIP-DILI); and one consortium coordinated by Roche seeks to develop research tools and diagnostics for autism spectrum disorder (EU-AIMS).
IMI also announced the launch of a Education and Training project called EUPATI, which shall create a European Patients’ Academy on Therapeutic Innovation. Its aim is to educate patients and the public about medicines development and empower patients to engage more effectively in the drug development process. The new projects mean that IMI is now supporting a total of 30 projects with a combined total cost of over €650m. IMI is a public-private partnership in health research and development. The European Union contributes €1 bn to the IMI research programme, which is matched by contributions worth at least another €1bn from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more